SCHEMBL359789

SCHEMBL359789

ClC[C]1CCCCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3913699 0.89
SCHEMBL2049187 0.81
SCHEMBL7737963 0.73
SCHEMBL3800070 0.73
SCHEMBL6605645 0.73
SCHEMBL7733149 0.73
SCHEMBL7741569 0.73
SCHEMBL247765 0.69 ALDH1A1 (0.35)
SCHEMBL7658464 0.69 ALDH1A1 (0.35)
SCHEMBL18549756 0.69 ALDH1A1 (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 200 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11780935-B2 Mutant antibodies and conjugation thereof PFIZER HEALTHCARE IRELAND (IE) 2023-10-10 US disclosed
US-20210147576-A1 MUTANT ANTIBODIES AND CONJUGATION THEREOF PFIZER HEALTHCARE IRELAND (IE) 2021-05-20 US disclosed
EP-2593142-B1 MULTIFUNCTIONAL ANTIBODY CONJUGATES COVX TECH IRELAND LIMITED (IE) 2018-10-10 EP disclosed
EP-2802355-B1 MUTANT ANTIBODIES AND CONJUGATION THEREOF COVX TECH IRELAND LIMITED (IE) 2018-09-05 EP disclosed
EP-3049391-A1 INDOL AND INDAZOL DERIVATIVES F. Hoffmann-La Roche AG (CH) 2016-08-03 EP disclosed
CN-101611053-B Anti-angiogenic compounds COVX TECHNOLOGIES IRELAND LTD 2015-06-03 CN disclosed
WO-2015044072-A1 INDOL AND INDAZOL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2015-04-02 WO disclosed
US-20150057431-A1 COMPOSITIONS FOR TREATING A DISEASE OR CONDITION ASSOCIATED WITH ABNORMAL ANGIOGENESIS COVX TECHNOLOGIES IRELAND LTD (IE) 2015-02-26 US disclosed
US-8937048-B2 Anti-angiogenic compounds COVX TECHNOLOGIES IRELAND, LIMITED (IE) 2015-01-20 US disclosed
US-8912148-B2 Methods of treating a disease or condition associated with abnormal angiogenesis COVX TECHNOLOGY IRELAND, LTD. (IE) 2014-12-16 US disclosed
US-20060074202-A1 Stabilized polycarbonate polyester composition GENERAL ELECTRIC COMPANY 2006-04-06 US disclosed
US-20060074155-A1 Halogen-free flame retardant polyester GENERAL ELECTRIC COMPANY 2006-04-06 US disclosed
US-20060069236-A1 Polyethersulfone compositions with high heat and good impact resistance GENERAL ELECTRIC COMPANY 2006-03-30 US disclosed
US-20060069222-A1 Curable formulations, cured compositions, and articles derived thereform GENERAL ELECTRIC COMPANY 2006-03-30 US disclosed
US-20060066004-A1 Method for controlling haze in an article comprising a polymer composition GENERAL ELECTRIC COMPANY 2006-03-30 US disclosed
US-20060069291-A1 Phosphazenium salt phase transfer catalysts GENERAL ELECTRIC COMPANY 2006-03-30 US disclosed
EP-1640403-A2 Polyethersulfone compositions with high heat and good impact resistance GENERAL ELECTRIC COMPANY (US) 2006-03-29 EP disclosed
EP-1640067-A2 Phosphazenium salt phase transfer catalysts GENERAL ELECTRIC COMPANY (US) 2006-03-29 EP disclosed
WO-2004091542-A2 NITROGEN CONTAINING INTEGRIN TARGETING COMPOUNDS COVX PHARMACEUTICALS, INC. (US) 2004-10-28 WO disclosed
US-6388044-B1 THERMOSETTING POLYETHER; CROSSLINKING BY HEATING SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-05-14 US disclosed